These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 30668188)

  • 1. Institute for clinical and economic review (ICER) psoriasis update 2018: what it means for dermatologists treating moderate-to-severe plaque psoriasis.
    Lee EB; Pithadia DJ; Reynolds KA; Wu JJ
    J Dermatolog Treat; 2019 Dec; 30(8):772-774. PubMed ID: 30668188
    [No Abstract]   [Full Text] [Related]  

  • 2. Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation.
    Corbett M; Chehadah F; Biswas M; Moe-Byrne T; Palmer S; Soares M; Walton M; Harden M; Ho P; Woolacott N; Bojke L
    Health Technol Assess; 2017 Oct; 21(56):1-326. PubMed ID: 28976302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.
    Tzanetakos C; Tzioufas A; Goules A; Kourlaba G; Theodoratou T; Christou P; Maniadakis N
    Rheumatol Int; 2017 Sep; 37(9):1441-1452. PubMed ID: 28523420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
    Woolacott N; Hawkins N; Mason A; Kainth A; Khadjesari Z; Vergel YB; Misso K; Light K; Chalmers R; Sculpher M; Riemsma R
    Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study.
    Wu N; Lee YC; Shah N; Harrison DJ
    Clin Ther; 2014 Aug; 36(8):1231-41, 1241.e1-3. PubMed ID: 25062652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guselkumab for the treatment of moderate-to-severe plaque psoriasis.
    Yang EJ; Sanchez IM; Beck K; Sekhon S; Wu JJ; Bhutani T
    Expert Rev Clin Pharmacol; 2018 Apr; 11(4):333-344. PubMed ID: 29478344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and economic review of secukinumab for moderate-to-severe plaque psoriasis.
    Wong IT; Shojania K; Dutz J; Tsao NW
    Expert Rev Pharmacoecon Outcomes Res; 2016; 16(2):153-66. PubMed ID: 26681527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic evaluation of systemic therapies for moderate to severe psoriasis.
    Sizto S; Bansback N; Feldman SR; Willian MK; Anis AH
    Br J Dermatol; 2009 Jun; 160(6):1264-72. PubMed ID: 19120346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Certolizumab Pegol in Plaque Psoriasis: Considerations for Pregnancy.
    Strain J; Leis M; Lee KO; Fleming P
    Skin Therapy Lett; 2021 Mar; 26(2):1-5. PubMed ID: 33769772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2).
    Gottlieb AB; Blauvelt A; Thaçi D; Leonardi CL; Poulin Y; Drew J; Peterson L; Arendt C; Burge D; Reich K
    J Am Acad Dermatol; 2018 Aug; 79(2):302-314.e6. PubMed ID: 29660421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological therapies for the treatment of severe psoriasis in patients with previous exposure to biological therapy: a cost-effectiveness analysis.
    Sawyer LM; Wonderling D; Jackson K; Murphy R; Samarasekera EJ; Smith CH
    Pharmacoeconomics; 2015 Feb; 33(2):163-77. PubMed ID: 25526841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimated cost efficacy of systemic treatments that are approved by the US Food and Drug Administration for the treatment of moderate to severe psoriasis.
    D'Souza LS; Payette MJ
    J Am Acad Dermatol; 2015 Apr; 72(4):589-98. PubMed ID: 25631851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Costs of therapy with biologics in the treatment of moderate to severe plaque psoriasis in the context of the Italian health-care system.
    Terranova L; Mattozzi C; Richetta AG; Mantuano M; Cardosi L; Teruzzi C
    G Ital Dermatol Venereol; 2014 Feb; 149(1):131-43. PubMed ID: 24566574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment of moderate-to-severe psoriasis in the UK.
    Johansson EC; Hartz S; Kiri SH; Kumar G; Svedbom A
    J Med Econ; 2018 Aug; 21(8):810-820. PubMed ID: 29873270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials.
    Blauvelt A; Reich K; Lebwohl M; Burge D; Arendt C; Peterson L; Drew J; Rolleri R; Gottlieb AB
    J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):546-552. PubMed ID: 30242918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Certolizumab pegol for the treatment of psoriasis.
    Campanati A; Benfaremo D; Luchetti MM; Ganzetti G; Gabrielli A; Offidani A
    Expert Opin Biol Ther; 2017 Mar; 17(3):387-394. PubMed ID: 28165828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT).
    Lebwohl M; Blauvelt A; Paul C; Sofen H; Węgłowska J; Piguet V; Burge D; Rolleri R; Drew J; Peterson L; Augustin M
    J Am Acad Dermatol; 2018 Aug; 79(2):266-276.e5. PubMed ID: 29660425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis.
    Bilal J; Berlinberg A; Bhattacharjee S; Trost J; Riaz IB; Kurtzman DJB
    J Dermatolog Treat; 2018 Sep; 29(6):569-578. PubMed ID: 29532693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
    Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
    Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Ramaekers BLT; Wolff RF; Pouwels X; Oosterhoff M; Van Giessen A; Worthy G; Noake C; Armstrong N; Kleijnen J; Joore MA
    Pharmacoeconomics; 2018 Aug; 36(8):917-927. PubMed ID: 29480455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.